Leprosy Mailing List – February 2, 2016
Ref.: (LML) Scientific Programme for the 19th International
Leprosy Congress, Beijing 2016
From: Cairns Smit, Aberdeen,
UK
Dear Colleagues,
This is a
message about the details of the Congress Scientific Programme for the 19th International
Leprosy Congress, Beijing 2016.
We
have developed a comprehensive programme of plenary sessions with leading
experts – see below.
There
will also be a series of Workshops and Congress sessions – see below.
On behalf of the Congress
Scientific committee,
Cairns Smith
Confirmed Plenary Sessions – 19th ILC
Inaugural session – organised by the China Organising Committee (I hour
- Ministers
- ILA
President
- WHO
Representative
- LEP
President
-
Novartis Foundation-
-
Nippon Foundation
-
China Association of People affected by leprosy
- Special Presentation: 60
years of leprosy control in China – Professor Zhang Guocheng
-
Special Keynote Lecture: Recent advances in research relevant to leprosy
– to be confirmed
Plenary 1: A Global
strategy for leprosy fit for purpose (1.5 hours)
Chair: Marcos Virmond
(ILA President, Brazil)
WHO Global Strategy for
Leprosy 2016-2020: accelerating towards a leprosy-free world – Drs Erwin
Cooreman and Laura Gillini (25 minutes)
Discussants:
Fit for national government (India)
Fit with
national government (Brazil) - Rosa Castalia
Fit with NGOs – Tanya Wood (ILEP)
Fit with needs of people affected leprosy – To be confirmed
Fit with NTDs – Emmy van der Grinten (Ghana)
Moderated Discussion: 30
minutes
Plenary 2: Innovations to reduce transmission (1.5hours)
Chair: Ann Aerts (Novartis
Foundation)
- What will U-MDT contribute to leprosy control? (JH
Kawuma - Uganda)
- The potential of chemoprophylaxis to reduce
transmission (Peter Steinmann - Switzerland)
- Can new diagnostic test improve control of
leprosy? (Fareed Mirza – Switzerland)
- Can novel vaccines become a reality? (Steve Reed -
USA)
Moderated Discussion (30
minutes)
Plenary 3: Advances in clinical management of leprosy
Chair: Shyamala Anand –
Clinical Ophthalmologist (India)
Understanding the pathology of
nerve injury in leprosy - Sergio L Antunes (Brazil)
Advances in dermatological
aspects of leprosy – Fu Ren Zhang (China)
Advances in the treatment of
reactions – Diana Lockwood (UK)
Integrated preventing
disability across NTDs – Linda Lehman (Brazil)
Moderated Discussion (30
minutes)
Plenary 4: Promoting inclusion of people affected by leprosy
Chair: Anwei Law (USA)
- Sociological aspects of barriers and facilitators
to inclusion - Cassandra White (USA)
- Evidence for interventions to reduce stigma- Ruth
Peters (Indonesia)
- Enabling participation of people affected by
leprosy - Michael Chen (HANDA, China)
- Making a difference to policy and practice –
Matthias Duck (Paraguay)
Moderated Discussion (30
minutes)
Workshops and Parallel Sessions
Workshops
1.
Definition of leprosy – sub-clinical and clinical
(David Scollard, USA/Claudio Salgado, Brazil)
2.
ENL reactions (Steve Walker - UK)
3.
U-MDT (Gerson Penna - Brazil)
4.
Chemoprophylaxis pilot studies (Bart vender Plaetse - Switzerland)
5.
Diagnostic tests (Annemeike Geluk - Netherlands)
6.
Changing discriminatory legislation (Sunil Anand - India)
7.
Drug resistance (Emanuelle Cambau - France)
8.
Clinical Problems Panel (Ben Naafs - Netherlands)
9.
History of leprosy update (Jo Robertson - Australia)
10. Molecular
biology and genetics (Milton Moraes - Brazil)
11. GIS and
Mapping (Paul Saunderson - Norway)
12. Enabling
enhanced participation (Hiroe Soyagimi - Japan)
13. Early
detection and transmission (Tom Gillis LRI 1 - USA)
14. Disability and
reactions (William Faber LRI 2 - Netherlands)
15. Inclusion
research (Wim van Brakel LRI 3 - Netherland)
16. Data systems
and new indicators for monitoring the global strategy. (Laura Gillini - India)
17. Molecular
biology and Genetics (U Gupta, JALMA - India)
18.
Epidemiological issues in preventing new disease occurrence (Chair – SK
Noordeen, India)
19. Leprosy
control in francophone Africa (Chair: Christian Johnson, Benin)
Congress Sessions
1.
Best clinical practice, health systems, training and referral
2.
Chemotherapy
3.
Reactions and nerve injury
4.
Dermatology
5.
Ophthalmology
6.
History
7.
Human rights and Discrimination
8.
Social aspects
9.
Participation
10. Immunology and
vaccines
11. Microbiology
12. Molecular
biology and Genetics
13. Epidemiology
14. Leprosy
Control
15. Prevention –
prophylaxis
16. Transmission
and diagnostics
17. Neglected
Tropical Diseases and other mycobacterial diseases
18. Nerve function
and impairments
19. Prevention of
disability
20. Rehabilitation
LML - S Deepak, B Naafs, S
Noto and P Schreuder
Contact: Dr Pieter Schreuder << editorlml@gmail.com
No comments:
Post a Comment